cts-1027
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00570336)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Matrix metalloproteinase 14INHIBITOR
Matrix metalloproteinase 14 inhibitor
- Matrix metalloproteinase 12INHIBITOR
Matrix metalloproteinase 12 inhibitor
- Matrix metalloproteinase 9INHIBITOR
Matrix metalloproteinase 9 inhibitor
- Matrix metalloproteinase-2INHIBITOR
Matrix metalloproteinase-2 inhibitor
- Matrix metalloproteinase 3INHIBITOR
Matrix metalloproteinase 3 inhibitor
- Matrix metalloproteinase 8INHIBITOR
Matrix metalloproteinase 8 inhibitor
- Matrix metalloproteinase 13INHIBITOR
MMP13 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1- Mol. weight
- 425.89 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL440498 ↗
Also known as
- cts-1027
- cts-1027
- cts-1027
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01273064 | Phase 2 | Jan 1, 2011 | Conatus Pharmaceuticals |
| NCT01051921 | Phase 2 | Jan 1, 2010 | Conatus Pharmaceuticals |
| NCT00925990 | Phase 2 | Jun 1, 2009 | Conatus Pharmaceuticals |
| NCT00570336 | Phase 2 | Dec 1, 2007 | Conatus Pharmaceuticals, FGK Clinical Research GmbH |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Conatus Pharmaceuticals | For profit | 4 | 4 | 1 | 2007 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1